logo
logo

Biostate AI secures $12M in Series A funding led by Accel to enhance RNA sequencing services for precision medicine.

May 20, 20252 months ago

Amount Raised

$12 Million

HoustonBiotechnology

Investors

Accel

Description

Biostate AI has completed a $12M Series A funding round to advance RNA sequencing for molecular diagnostics. Led by Accel, the funding aims to revolutionize accessibility and integration of precision medicine. Co-founders Ashwin Gopinath and David Zhang focus on utilizing comprehensive RNA analyses. Their goal is to create predictive models that lead to personalized therapeutics.

Company Information

Company

Biostate AI

Location

Houston, Texas, United States

About

Biostate AI is a startup building generative AI that predicts the evolution of human disease and drug response based on RNA sequencing data. Its patented wetlab technologies, including BIRT, allow affordable and scalable collection of massive amounts of transcriptomic and genomic data. With sites in Houston, TX, Palo Alto, CA, Bangalore, India, and Shanghai, China, Biostate AI is a global company with collaborations with top hospitals, academic researchers, and biotech/biopharma companies. Biostate AI was founded by serial entrepreneurs and former professors David Zhang (Rice U.) and Ashwin Gopinath (MIT) and is backed by top investors and experts including Accel, Dario Amodei (Anthropic), Emily Leproust (Twist Biosciences), and Mike Schnall-Levin (10X Genomics).

Related People

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech